Related Experiment Videos
Gabapentin modifies extracellular opioid peptide content in amygdala: a microdialysis study
L Rocha1, R Ondarza-Rovira, N T Maidment
1Instituto Mexicano de Psiquiatría, División de Neurociencias, Mexico, D.F. rocha@cenids.ssa.gob.mx
Epilepsy Research
|May 8, 1999
Summary
Gabapentin increases opioid peptide release in rat amygdala, but not hippocampus. This enhanced release of Leu- and Met-enkephalin may contribute to gabapentin's therapeutic and adverse effects.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Gabapentin is an anticonvulsant medication.
- The amygdala plays a role in processing emotions and seizures.
- Opioid peptides are endogenous neurotransmitters involved in pain and mood regulation.
Purpose of the Study:
- To investigate the effect of gabapentin on opioid peptide release in specific brain regions.
- To determine if gabapentin influences opioid peptide levels in the amygdala and hippocampus.
Main Methods:
- Microdialysis was used to measure extracellular opioid peptide levels in freely moving rats.
- Rats received a single oral dose of gabapentin.
- High-performance liquid chromatography (HPLC) identified specific opioid peptides.
Main Results:
- Gabapentin significantly increased extracellular opioid peptide levels in the amygdala at 60 and 90 minutes post-administration.
- Opioid peptide levels returned to basal levels by 120 minutes.
- No significant changes in opioid peptide levels were observed in the hippocampus.
- Leu-enkephalin and Met-enkephalin were the primary opioid peptides identified in the amygdala.
Conclusions:
- Gabapentin administration induces a transient increase in amygdala opioid peptide release.
- This enhanced opioid peptide release in the amygdala may be linked to gabapentin's antiepileptic properties.
- The findings suggest a potential role for opioid peptide modulation in gabapentin's adverse effects.